TARS
Tarsus Pharmaceuticals, Inc.
TARS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
TARS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
TARS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
TARS PE Valuation
TARS has no meaningful PE right now: it lost money over the past year.
TARS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TARS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TARS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.16 | -$13.17 |
| Q2 2026 | -$1.06 | +$1.24 |
| Q1 2026 | -$1.11 | +$1.59 |
| Q4 2025 | -$1.59 | +$1.48 |
| Q3 2025 | -$1.99 | +$1.80 |
| Q2 2025 | -$2.30 | +$2.16 |
| Q1 2025 | -$2.70 | +$2.05 |
| Q4 2024 | -$3.07 | +$1.55 |
TARS lost $15.16 per share over the past year, a bigger loss than the year before.
TARS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $194.6M | +64% |
| Q2 2026 | $173.9M | +69% |
| Q1 2026 | $162.1M | +107% |
| Q4 2025 | $151.7M | +128% |
| Q3 2025 | $118.7M | +147% |
| Q2 2025 | $102.7M | +152% |
| Q1 2025 | $78.3M | +184% |
| Q4 2024 | $66.4M | +408% |
TARS's revenue has grown year over year for 11 quarters in a row: $195M last quarter, up 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -340% | -328 points |
| Q2 2026 | -11% | +10 points |
| Q1 2026 | -3.8% | +30 points |
| Q4 2025 | -5.3% | +32 points |
| Q3 2025 | -12% | +40 points |
| Q2 2025 | -22% | +60 points |
| Q1 2025 | -34% | +103 points |
| Q4 2024 | -37% | +303 points |
TARS's operating margin was −340% last quarter, down 328 points from the same quarter a year ago.
TARS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -144% |
| Q2 2026 | $57.2M | +$87.5M |
| Q1 2026 | -$30.5M | -$9.2M |
| Q4 2025 | $13M | +$35.2M |
| Q3 2025 | $16.3M | +$25.3M |
| Q2 2025 | -$30.4M | -$14.9M |
| Q1 2025 | -$21.2M | +$16.7M |
| Q4 2024 | -$22.3M | +$17.1M |
TARS's free cash flow has turned positive after six years mostly in the red: $32M over the past year.
TARS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +3M shares |
| 1 year | +9% | +3.8M shares |
| 3 years | +52% | +15.8M shares |
| 5 years | +125% | +25.8M shares |
| Available history | +326% | +35.5M shares |
TARS has 46M diluted shares, up 9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | $1,000 |
| Q1 2020 | $27,000 |
| Q4 2019 | — |
TARS Net Leverage
TARS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TARS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 44.3 | Neutral |
TARS's weekly RSI is 56 (neutral) and its Stochastic is 44 (neutral).
TARS PE vs Healthcare Sector
TARS has no meaningful PE right now: it lost money over the past year.
TARS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 6.3% above |
| 20 week MA | $70.3 | 9.4% above |
| 50 week MA | $69.2 | 11% above |
| 100 week MA | $60.9 | 26% above |
| 200 week MA | $42.9 | 79% above |
TARS is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
TARS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $44.0 | +114% |
| 2021 | $44.0 | $25.9 | -41% |
| 2022 | $25.9 | $14.5 | -44% |
| 2023 | $14.5 | $20.3 | +40% |
| 2024 | $20.3 | $55.0 | +172% |
| 2025 | $55.0 | $81.8 | +49% |
| 2026 YTD | $81.8 | $76.9 | -6% |
TARS's yearly returns have swung widely, from +172% in 2024 to −44% in 2022. It's down 6% so far in 2026.